Sub Population Insights for Precision Medicine towards Regulatory and Commercial Success
August 12, 2020
11:00AM - 12:00PM (GMT -04:00) Eastern Daylight Time

Regulatory and commercial success of drug assets depend upon how well available data including mechanism of action, off-label uses, side-effects and subpopulation efficacy are analyzed and incorporated into the product strategy. Conducting such thorough analysis before committing funds into a trial can save sponsors more than a billion dollars as well as years of valuable time developing a drug. These analyses can be performed through the use of artificial intelligence (AI) and machine learning-driven platforms that identify sub-populations of patients in real world data as well as in clinical trial data for safety, efficacy and side-effects. When sponsors can find these populations and adapt the trial design accordingly, it can reduce the rate of trial failure, rescue a promising molecule for further development, and capture better primary and secondary endpoint data to support approval, asset valuations and payer reimbursements.

Joining this webinar you will:

  • Understand current payer, provider, regulatory and technology trends
  • Learn how sub-population analysis in trial design and precision medicine can add valuable insights across the development process
  • Hear case studies from Oncology and see how the results of sub-population analysis could help sponsors make important decisions about the future of a drug assets earlier
  • Find out various R&D and Commercial applications of sub-population analysis



Michael Kleinrock

Sr. Dir., Research Development, IQVIA Institute for Human Data Science

Russel Reeve

Vice President, Head of Biostatistics & Decision Science, IQVIA 

Jeff Hodge

Vice President, Development Solutions, Oncology CoE, IQVIA 

Kal Chaudhuri

Principal, Subpopulation Optimization and Modeling Solutions, IQVIA

Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.

Media Inquiries

Please use this form to reach out to our media team with inquiries. Thank you.